Bradley A Maron1, William M Oldham2, Stephen Y Chan2, Sara O Vargas2, Elena Arons2, Ying-Yi Zhang2, Joseph Loscalzo2, Jane A Leopold2. 1. From the Divisions of Cardiovascular Medicine (B.A.M., S.Y.C., E.A., Y.-Y.Z., J.L., J.A.L.) and Pulmonary and Critical Care Medicine (W.M.O.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Department of Cardiology, Veterans Affairs Boston Healthcare System, Boston, MA (B.A.M.); and Department of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, MA (S.O.V.). bmaron@partners.org. 2. From the Divisions of Cardiovascular Medicine (B.A.M., S.Y.C., E.A., Y.-Y.Z., J.L., J.A.L.) and Pulmonary and Critical Care Medicine (W.M.O.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Department of Cardiology, Veterans Affairs Boston Healthcare System, Boston, MA (B.A.M.); and Department of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, MA (S.O.V.).
Abstract
BACKGROUND: The molecular mechanism(s) regulating hypoxia-induced vascular fibrosis are unresolved. Hyperaldosteronism correlates positively with vascular remodeling in pulmonary arterial hypertension, suggesting that aldosterone may contribute to the pulmonary vasculopathy of hypoxia. The hypoxia-sensitive transcription factors c-Fos/c-Jun regulate steroidogenic acute regulatory protein (StAR), which facilitates the rate-limiting step of aldosterone steroidogenesis. We hypothesized that c-Fos/c-Jun upregulation by hypoxia activates StAR-dependent aldosterone synthesis in human pulmonary artery endothelial cells (HPAECs) to promote vascular fibrosis in pulmonary arterial hypertension. METHODS AND RESULTS: Patients with pulmonary arterial hypertension, rats with Sugen/hypoxia-pulmonary arterial hypertension, and mice exposed to chronic hypoxia expressed increased StAR in remodeled pulmonary arterioles, providing a basis for investigating hypoxia-StAR signaling in HPAECs. Hypoxia (2.0% FiO2) increased aldosterone levels selectively in HPAECs, which was confirmed by liquid chromatography-mass spectrometry. Increased aldosterone by hypoxia resulted from enhanced c-Fos/c-Jun binding to the proximal activator protein-1 site of the StAR promoter in HPAECs, which increased StAR expression and activity. In HPAECs transfected with StAR-small interfering RNA or treated with the activator protein-1 inhibitor SR-11302 [3-methyl-7-(4-methylphenyl)-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid], hypoxia failed to increase aldosterone, confirming that aldosterone biosynthesis required StAR activation by c-Fos/c-Jun. The functional consequences of aldosterone were confirmed by pharmacological inhibition of the mineralocorticoid receptor with spironolactone or eplerenone, which attenuated hypoxia-induced upregulation of the fibrogenic protein connective tissue growth factor and collagen III in vitro and decreased pulmonary vascular fibrosis to improve pulmonary hypertension in vivo. CONCLUSION: Our findings identify autonomous aldosterone synthesis in HPAECs attributable to hypoxia-mediated upregulation of StAR as a novel molecular mechanism that promotes pulmonary vascular remodeling and fibrosis.
BACKGROUND: The molecular mechanism(s) regulating hypoxia-induced vascular fibrosis are unresolved. Hyperaldosteronism correlates positively with vascular remodeling in pulmonary arterial hypertension, suggesting that aldosterone may contribute to the pulmonary vasculopathy of hypoxia. The hypoxia-sensitive transcription factors c-Fos/c-Jun regulate steroidogenic acute regulatory protein (StAR), which facilitates the rate-limiting step of aldosterone steroidogenesis. We hypothesized that c-Fos/c-Jun upregulation by hypoxia activates StAR-dependent aldosterone synthesis in human pulmonary artery endothelial cells (HPAECs) to promote vascular fibrosis in pulmonary arterial hypertension. METHODS AND RESULTS:Patients with pulmonary arterial hypertension, rats with Sugen/hypoxia-pulmonary arterial hypertension, and mice exposed to chronic hypoxia expressed increased StAR in remodeled pulmonary arterioles, providing a basis for investigating hypoxia-StAR signaling in HPAECs. Hypoxia (2.0% FiO2) increased aldosterone levels selectively in HPAECs, which was confirmed by liquid chromatography-mass spectrometry. Increased aldosterone by hypoxia resulted from enhanced c-Fos/c-Jun binding to the proximal activator protein-1 site of the StAR promoter in HPAECs, which increased StAR expression and activity. In HPAECs transfected with StAR-small interfering RNA or treated with the activator protein-1 inhibitor SR-11302 [3-methyl-7-(4-methylphenyl)-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid], hypoxia failed to increase aldosterone, confirming that aldosterone biosynthesis required StAR activation by c-Fos/c-Jun. The functional consequences of aldosterone were confirmed by pharmacological inhibition of the mineralocorticoid receptor with spironolactone or eplerenone, which attenuated hypoxia-induced upregulation of the fibrogenic protein connective tissue growth factor and collagen III in vitro and decreased pulmonary vascular fibrosis to improve pulmonary hypertension in vivo. CONCLUSION: Our findings identify autonomous aldosterone synthesis in HPAECs attributable to hypoxia-mediated upregulation of StAR as a novel molecular mechanism that promotes pulmonary vascular remodeling and fibrosis.
Authors: Victoria N Parikh; Richard C Jin; Sabrina Rabello; Natali Gulbahce; Kevin White; Andrew Hale; Katherine A Cottrill; Rahamthulla S Shaik; Aaron B Waxman; Ying-Yi Zhang; Bradley A Maron; Jochen C Hartner; Yuko Fujiwara; Stuart H Orkin; Kathleen J Haley; Albert-László Barabási; Joseph Loscalzo; Stephen Y Chan Journal: Circulation Date: 2012-02-27 Impact factor: 29.690
Authors: Mardi Gomberg-Maitland; Todd M Bull; Rajeev Saggar; Robyn J Barst; Amany Elgazayerly; Thomas R Fleming; Friedrich Grimminger; Maurizio Rainisio; Duncan J Stewart; Norman Stockbridge; Carlo Ventura; Ardeschir H Ghofrani; Lewis J Rubin Journal: J Am Coll Cardiol Date: 2013-12-24 Impact factor: 24.094
Authors: Bradley A Maron; Ying-Yi Zhang; Kevin White; Stephen Y Chan; Diane E Handy; Christopher E Mahoney; Joseph Loscalzo; Jane A Leopold Journal: Circulation Date: 2012-07-11 Impact factor: 29.690
Authors: S R King; A A Matassa; E K White; L P Walsh; Y Jo; R M Rao; D M Stocco; M E Reyland Journal: J Mol Endocrinol Date: 2004-04 Impact factor: 5.098
Authors: Jason M Elinoff; Adrien J Mazer; Rongman Cai; Mengyun Lu; Grace Graninger; Bonnie Harper; Gabriela A Ferreyra; Junfeng Sun; Michael A Solomon; Robert L Danner Journal: Am J Physiol Lung Cell Mol Physiol Date: 2019-10-16 Impact factor: 5.464
Authors: Steven C Pugliese; Sushil Kumar; William J Janssen; Brian B Graham; Maria G Frid; Suzette R Riddle; Karim C El Kasmi; Kurt R Stenmark Journal: J Immunol Date: 2017-05-12 Impact factor: 5.422
Authors: Anna Klinke; Torben Schubert; Marion Müller; Ekaterina Legchenko; Jason G E Zelt; Tsukasa Shimauchi; L Christian Napp; Alexander M K Rothman; Sébastien Bonnet; Duncan J Stewart; Georg Hansmann; Volker Rudolph Journal: Cardiovasc Diagn Ther Date: 2020-10